SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51053I don't disagree with statements about political pressure. Elections a year JamesK29/7/2019
51052VKTX managememts (CEO) was not honest in presentation of the statue for NASH canMiljenko Zuanic-9/7/2019
51051The bio/pharma model isn't broken, but it is expensive. The cost of developArt Bechhoefer-9/6/2019
51050VKTX is much smaller than FGEN or IONS, but given its size and the fact that it Art Bechhoefer-9/6/2019
51049< The system just cannot sustain the costs.> The R$D cost are abnormal hiMiljenko Zuanic-9/6/2019
51048The bio/pharma model is broken. The system just cannot sustain the costs. A downRobohogs-9/6/2019
51047The article you cited gives some essential answers: Demand for new, innovative dArt Bechhoefer19/6/2019
51046What happens to the biotech sector if we fall into recession??? sickeconomics.cSickEconomist-9/6/2019
51045Thanks for posting that. A very interesting man. I had no idea. AshleyA.J. Mullen-9/5/2019
51044cmc.eduJoe Wesley-9/5/2019
51043From Claremont College In Memoriam: Trustee Thomas B. Neff ’76 P’21 August 29, Joe Wesley49/5/2019
51042A plethora of articles citing this news that Ritalin/Concerta alter brains in yoRobohogs-9/5/2019
51041More information: finance.yahoo.comA.J. Mullen-8/26/2019
51040Thomas Neff, CEO and CoB of FGEN died unexpectedly over the weekend, seekingalphA.J. Mullen-8/26/2019
51039A valuation case study..... sickeconomics.comSickEconomist-8/24/2019
51038>>Not sure how revenues flow to FGEN from the chinese entity though. It&#Biomaven-8/23/2019
51037I guess the needle might get moved if the gov't decides to pay for DD and/oratticus4paws-8/22/2019
51036China approves Roxadustat for chronic kidney disease(CKD, including non-dialysisA.J. Mullen18/21/2019
51035China adds 148 drugs to key insurance list: state media BEIJING/SHANGHAI (Reutejb118-8/21/2019
51034UCSF has some high profile clinicians who also publish/run trials, teach etc Broldirtybastard-8/19/2019
51033SESN-Sesen Bio: One Step Closer To FDA Approval - An Update seekingalpha.comCeltictrader-8/19/2019
51032GSK's dapro may in fact have a trial in NDD vs. PBO. It does: ASCEND-NHQ btuck-8/18/2019
51031<<1. For the first time (i.e., the first quarterly report), FGEN reported quidditch38/18/2019
51030OT - need MS specialist in San Francisco. I have a young friend that is a likelIRWIN JAMES FRANKEL-8/17/2019
51029CELG I'm starting to wonder if they will be able to sell Otezla. Seems likIRWIN JAMES FRANKEL-8/17/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News